文献速递糖尿病肥胖与代谢综合征

脑啡肽酶抑制:2型糖尿病治疗新选择?

Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
PubMed 文献 · Diabetologia · 2019-05-14

本文综述了脑啡肽酶抑制在糖代谢中的作用。人和临床前研究显示,双重血管紧张素受体-脑啡肽酶抑制剂(ARNi)可改善2型糖尿病和/或肥胖者的血糖控制与胰岛素敏感性。作者认为脑啡肽酶抑制剂可能成为2型糖尿病治疗选择,但需与血管紧张素II受体阻滞剂联用以规避单药抑制的不良后果。

要点

  • ARNi在2型糖尿病和/或肥胖人群中改善血糖控制与胰岛素敏感性
  • 脑啡肽酶抑制剂已获批用于心衰,具备重定位治疗2型糖尿病的潜力
  • 单用脑啡肽酶抑制剂可能带来不良后果,需与血管紧张素II受体阻滞剂联用

核心结论

  • 脑啡肽酶抑制剂可能是治疗2型糖尿病的有用选择,但需与血管紧张素II受体阻滞剂联用以规避单药抑制的不良后果。

研究设计与样本

  • 本文为综述,评估脑啡肽酶被删除/抑制的临床前和临床研究证据,并汇总相关机制、潜在不良效应及对糖尿病并发症的影响。

主要发现

  • 近期人体研究中,双重血管紧张素受体-脑啡肽酶抑制剂(ARNi)改善2型糖尿病和/或肥胖者的血糖控制与胰岛素敏感性。
  • 临床前研究报道,脑啡肽酶抑制单独或联合肾素-血管紧张素系统阻滞剂对血糖稳态产生有益效应。
  • 脑啡肽酶抑制除血糖控制外,对糖尿病并发症亦有有利影响。

临床怎么用

  • 脑啡肽酶抑制剂已获批用于心力衰竭,考虑将其重定位用于2型糖尿病治疗时应与血管紧张素II受体阻滞剂联用。

局限性

  • 单用脑啡肽酶抑制剂可能存在限制其临床疗效与安全性的不良效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neprilysin is a widely expressed peptidase with broad substrate specificity that preferentially hydrolyses oligopeptide substrates, many of which regulate the cardiovascular, nervous and immune systems. Emerging evidence suggests that neprilysin also hydrolyses peptides that play an important role in glucose metabolism. In recent studies in humans, a dual angiotensin receptor-neprilysin inhibitor (ARNi) improved glycaemic control and insulin sensitivity in individuals with type 2 diabetes and/or obesity. Moreover, preclinical studies have also reported that neprilysin inhibition, alone or in combination with renin-angiotensin system blockers, elicits beneficial effects on glucose homeostasis. Since neprilysin inhibitors have been approved for the treatment of heart failure, their repurposing for treating type 2 diabetes would provide a novel therapeutic strategy. In this review, we evaluate existing evidence from preclinical and clinical studies in which neprilysin is deleted/inhibited, we highlight potential mechanisms underlying the beneficial glycaemic effects of neprilysin inhibition, and discuss possible deleterious effects that may limit the efficacy and safety of neprilysin inhibitors in the clinic. We also review the favourable impact neprilysin inhibition can have on diabetic complications, in addition to glucose control. Finally, we conclude that neprilysin inhibitors may be a useful therapeutic option for treating type 2 diabetes; however, their combination with angiotensin II receptor blockers is needed to circumvent deleterious consequences of neprilysin inhibition alone.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Esser N, Zraika S. Neprilysin inhibition: a new therapeutic option for type 2 diabetes? Diabetologia. 2019. PMID: 31089754. doi:10.1007/s00125-019-4889-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。